News

Lotus Pharmaceuticals (Lotus) has reported that Liang Fang, a controlled operating entity of Lotus has appointed Jinzhong Han as a general manager of the company’s over-the-counter drug division

Critical Outcome Technologies (COTI) has announced positive results from animal experiments carried out at a prominent Canadian cancer research facility. This new series of experiments adds to the

Access has provided an update on the European commercial launch of its MuGard, an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and

Sanofi-aventis and Alopexx Pharmaceuticals have entered into a collaboration agreement and option for a license on a first-in-class human monoclonal antibody for the prevention and treatment of S

Biomoda has reported that the Helen F. Graham Cancer Center associated with Christiana Care Health System, will recruit a cohort of patients diagnosed with lung cancer to participate

Bayer Schering Pharma’s first Phase II trial with oral agent Riociguat (BAY 63-2521) in pulmonary hypertension, owing to interstitial lung disease (PH-ILD), has successfully been completed. The primary

AdvanDx has received FDA 510(k) clearance for a 90 minutes protocol for its S. aureus PNA FISH and S. aureus/CNS PNA FISH tests. The protocol reduces the PNA

Celgene UK has announced that preliminary clinical data from a phase III, randomized, double-blind study of elderly patients newly diagnosed with multiple myeloma, were presented during the 51st

Genomic Health has reported that The Lancet Oncology has published positive results from a study of Oncotype DX in postmenopausal women with node-positive, estrogen receptor-positive breast cancer. The